{"id":14578,"date":"2016-02-05T09:52:21","date_gmt":"2016-02-05T09:52:21","guid":{"rendered":"http:\/\/www.asperbio.com\/?page_id=14578"},"modified":"2023-08-29T01:47:07","modified_gmt":"2023-08-28T22:47:07","slug":"venoosne-trombemboolia","status":"publish","type":"page","link":"https:\/\/www.asperbio.com\/et\/asper-cardiogenetics-testid\/venoosne-trombemboolia\/","title":{"rendered":"Trombofiilia"},"content":{"rendered":"<h2>Trombofiilia p\u00e4riliku eelsoodumuse m\u00e4\u00e4ramine<\/h2>\n<div class=\"sm_post_content\" style=\"background: url('https:\/\/www.asperbio.com\/wp-content\/uploads\/Cardio-01.png') repeat-y; padding-left: 40px;\">\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Geenid:<\/strong><\/td>\n<td>Factor V, prothrombin\/Factor II, <em>MTHFR<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #e63458; background-color: #a34c95; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Markerid:<\/strong><\/td>\n<td>4<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #e63458; background-color: #a34c95; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Metoodika:<\/strong><\/td>\n<td>Sanger sekveneerimine<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #e63458; background-color: #a34c95; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Testi valmimisaeg:<\/strong><\/td>\n<td>1-2 n\u00e4dalat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #e63458; background-color: #a34c95; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>N\u00f5uded proovi-materjalile:<\/strong><\/td>\n<td>2-4 ml t\u00e4isverd antikoagulandiga EDTA (lilla korgiga katsuti)<\/p>\n<p>300 ng DNA-d elueerituna TE, AE puhvris v\u00f5i steriilses vees, kontsentratsiooniga 100-250 ng\/\u00b5l<br \/>\nDNA saata toatemperatuuril v\u00f5i k\u00fclmutatuna. A260\/A280 suhe peaks olema 1.8-2.0. DNA peab agaroosgeelis pikkusmarkeri juuresolekul olema detekteeritav \u00fche tervikliku b\u00e4ndina.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #e63458; background-color: #a34c95; height: 2px; border: none; width: 100%;\" \/>\n<table class=\"table no-border no-margin\" border=\"0\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td width=\"110\"><strong>Tellimine:<\/strong><\/td>\n<td>Proovimaterjal saata koos <span style=\"color: #a34c95;\"><strong><a style=\"color: #a34c95;\" href=\"https:\/\/www.asperbio.com\/wp-content\/uploads\/Asper-Cardiogenetics-saatekiri.doc\">saatekirjaga<\/a><\/strong><\/span> Asper Biogene laborisse<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr style=\"color: #e63458; background-color: #a34c95; height: 2px; border: none; width: 100%;\" \/>\n<\/div>\n<p><strong><br \/>\nN\u00e4idustused geenitesti tegemiseks:<\/strong><\/p>\n<ol>\n<li>Venoosne tromboos &lt;50-aastaselt<\/li>\n<li>Korduv venoosne tromboos pereliikmetel<\/li>\n<li>Perekonnas esineb teadaolev venoosse trombemboolia riski suurendav geenivariant<\/li>\n<li>S\u00fcdamelihase infarkt &lt;50\u2013aastastel suitsetavatel naistel<\/li>\n<li>Naistel venoosne tromboos suukaudsete rasestumisvastaste ravimite v\u00f5tmise foonil<\/li>\n<li>Rasedusaegsete komplikatsioonide esinemisel (korduvad raseduse katkemised, preeklampsia v\u00f5i nuris\u00fcnnitus)<\/li>\n<\/ol>\n<p><strong>Trombofiilia<\/strong>, millele on iseloomulik <strong>venoosne trombemboolia<\/strong> (VTE) v\u00f5ib v\u00e4ljenduda kahe omavahel seotud haigusseisundina. Esimene neist, <strong>s\u00fcvaveeni tromboos<\/strong> (SVT), t\u00e4hendab trombi tekkimist m\u00f5nes keha s\u00fcvaveenidest, tavaliselt jalgades. Teine, <strong>kopsuarteri trombemboolia<\/strong> (KATE), tekib juhul, kui s\u00fcvaveenis tekkinud tromb p\u00e4\u00e4seb sealt liikuma ja j\u00f5uab vereringe kaudu kopsu. Juhul, kui vajalikku ravi ei saa piisavalt kiiresti, v\u00f5ib kopsuarteri trombemboolia osutuda eluohtlikuks.<\/p>\n<p>VTE on multifaktoriaalne haigus, mis tekib enamasti siis, kui mitmed riskifaktorid (geneetilised ja elu jooksul omandatud) esinevad samaaegselt. Elu jooksul omandatud riskifaktorite m\u00f5ju on oluliselt suurem geneetilise riskifaktori olemasolul. K\u00f5ige olulisemateks omandatud riskiteguriteks peetakse ulatuslikke operatsioone\/traumasid. Keskmise tugevusega riskifaktorid on rasedus, hormoonasendusravi v\u00f5i rasestumisvastaste tablettide kasutamine, s\u00fcnnitusj\u00e4rgne periood ja kasvajad. V\u00e4iksemateks riskifaktoriteks peetakse liikumatust\/sundasendit j\u00e4seme immobiliseerimise, pikaajalise lennureisi ja halvatuse t\u00f5ttu.<\/p>\n<p>Kaasas\u00fcndinud ehk geneetilisteks teguriteks, mis soodustavad VTE tekkimist, on <strong>F5 (faktor V) geeni Leideni mutatsiooni<\/strong> (FVL), <strong>F2 (faktor II, protrombiin)<\/strong> geeni mutatsiooni 20210G&gt;A, <strong>MTHFR<\/strong> geenivariantide 677C&gt;T ja 1298A&gt;C riskialleelide esinemine. Lisaks neile neljale sagedamini esinevale geneetilisele riskifaktorile, on kirjeldatud veel teisi geneetilisi riskifaktoreid, kuid mille esinemissagedus on v\u00e4ga madal ja\/v\u00f5i nad m\u00f5jutavad VTE tekke riski v\u00e4hemal m\u00e4\u00e4ral.<\/p>","protected":false},"excerpt":{"rendered":"<p>Trombofiilia p\u00e4riliku eelsoodumuse m\u00e4\u00e4ramine Geenid: Factor V, prothrombin\/Factor II, MTHFR Markerid: 4 Metoodika: Sanger sekveneerimine Testi valmimisaeg: 1-2 n\u00e4dalat N\u00f5uded proovi-materjalile: 2-4 ml t\u00e4isverd antikoagulandiga EDTA (lilla korgiga katsuti) 300 ng DNA-d elueerituna TE, AE puhvris v\u00f5i steriilses vees, kontsentratsiooniga 100-250 ng\/\u00b5l DNA saata toatemperatuuril v\u00f5i k\u00fclmutatuna. A260\/A280 suhe peaks olema 1.8-2.0. DNA peab agaroosgeelis [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":14537,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-14578","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/14578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/comments?post=14578"}],"version-history":[{"count":3,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/14578\/revisions"}],"predecessor-version":[{"id":29001,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/14578\/revisions\/29001"}],"up":[{"embeddable":true,"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/pages\/14537"}],"wp:attachment":[{"href":"https:\/\/www.asperbio.com\/et\/wp-json\/wp\/v2\/media?parent=14578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}